8-K: Establishment Labs Appoints Peter Caldini as Chief Executive Officer

Establishment Labs Holdings Inc. appoints Fillipo 'Peter' Caldini as its permanent Chief Executive Officer, effective May 7, 2025, after he served as interim CEO.

Summary

• Establishment Labs Holdings Inc. has appointed Fillipo 'Peter' Caldini as Chief Executive Officer, effective May 7, 2025.
• Caldini previously served as Interim CEO since March 1, 2025.
• He has also been appointed as a Class II director, effective May 24, 2025.
• The appointment follows an extensive search process.
• The company aims to turn EBITDA positive in 2025 and cash flow positive in 2026.
• Establishment Labs has delivered over four million Motiva devices since 2010.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of a permanent CEO, the company's growth targets, and the continued involvement of the founder. The focus on innovation and market expansion further contributes to the positive outlook.

Positives

• The appointment of a permanent CEO provides leadership stability.
• The company is targeting EBITDA positive in 2025 and cash flow positive in 2026.
• Establishment Labs has a differentiated product suite in the medtech industry.
• The company has a strong history with over four million Motiva devices delivered since 2010.
• The founder, Juan Jos Chacn-Quirs, remains involved as a board member.

Future Outlook

Establishment Labs aims to achieve EBITDA positivity in 2025 and cash flow positivity in 2026, while expanding its market presence and continuing innovation.

Management Comments

• 'With his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs,' commented Nick Lewin, Chairman of the Board of Establishment Labs.
• 'It is an honor to be leading Establishment Labs,' added Peter Caldini.
• Peter Caldini stated that the company is in a unique position to innovate and expand in the market.

Industry Context

The appointment of a permanent CEO signals stability and focus as Establishment Labs aims to expand its presence in the global medical technology market, particularly in breast aesthetics and reconstruction. The company's focus on innovation and operational excellence aligns with industry trends emphasizing patient safety and satisfaction.

Comparison to Industry Standards

• Establishment Labs competes with companies like Allergan (now AbbVie), Mentor (Johnson & Johnson), and Sientra in the breast implant market.
• The company's focus on minimally invasive technologies like Mia Femtech and Preserv aligns with the industry's shift towards less invasive procedures.
• The goal of achieving EBITDA positivity in 2025 and cash flow positivity in 2026 is a common objective for growth-stage medical device companies.
• The delivery of over four million Motiva devices since 2010 indicates a significant market presence and adoption of the company's products.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of a permanent CEO and the company's financial targets may positively influence investor confidence.
• Employees: The new leadership may bring changes in strategy and operations.
• Customers: Continued innovation and focus on patient safety may lead to improved products and services.
• Plastic Surgeons: Continued support and advocacy from the founder may strengthen relationships with the plastic surgery community.

Next Steps

• Peter Caldini will assume his responsibilities as CEO and Class II director.
• The company will focus on achieving EBITDA positivity in 2025 and cash flow positivity in 2026.
• Establishment Labs will continue to innovate and expand its market presence.

Key Dates

Keywords

Establishment Labs, Peter Caldini, Chief Executive Officer, Appointment, Motiva, Breast Aesthetics, Breast Reconstruction, Medical Technology